CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease.
about
The two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brainNeuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptorsPresenilin-1 familial Alzheimer's disease mutation alters hippocampal neurogenesis and memory function in CCL2 null mice.Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer's disease model.Phagocytosis of microglia in the central nervous system diseasesNoradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications.The impact of microglial activation on blood-brain barrier in brain diseases.The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradationIntravenous ascorbate improves spatial memory in middle-aged APP/PSEN1 and wild type mice.Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.The Potential Role of Chemokines in Alzheimer's Disease Pathogenesis.The complex contribution of chemokines to neuroinflammation: switching from beneficial to detrimental effects.Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?Impact of Cytokines and Chemokines on Alzheimer's Disease Neuropathological Hallmarks.Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer's Disease.APOE genotype-dependent modulation of astrocyte chemokine CCL3 production.Dual effects of noradrenaline on astroglial production of chemokines and pro-inflammatory mediatorsThe scavenging chemokine receptor ACKR2 has a significant impact on acute mortality rate and early lesion development after traumatic brain injury.Necroptosis in microglia contributes to neuroinflammation and retinal degeneration through TLR4 activation.Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer's Disease and Mild Cognitive Impairment: A Two-year Follow-up Study.Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for Alzheimer's disease?Complex role of chemokine mediators in animal models of Alzheimer's Disease.Anti-retroviral drugs: current state and development in the next decade.URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease.Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice.Potential Effects of MSC-Derived Exosomes in Neuroplasticity in Alzheimer's DiseaseDifferential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model
P2860
Q26824833-8DDA183D-BE39-4B3E-A3FF-C69C68F3639CQ26995483-8AED64FF-CBDE-4792-8D1F-B427E5CD3C4EQ27331488-B2BD95B2-3EFF-43CD-9F13-8BBB576BF1BAQ30846817-67F18204-3BF8-4757-A855-B8FF980662D2Q33574527-D2C6E0EE-9E1F-40C6-8E3F-B878A0DCC010Q34391616-159970B1-395A-4E00-8D0F-D9ED9D2BDB3FQ34442604-72F6FCFF-9D3A-4B3D-B28E-52A176C916FEQ37085168-E391F319-BFFE-4FF0-9023-F68FBD0B515DQ37693458-4D9EE0C0-3A33-4135-A41F-E54C1658D277Q38082670-A6798356-3322-4DF8-BFC0-351364957407Q38152999-13F3D9C9-8628-4F60-9C5F-79C97192A7D0Q38177234-CDCAB324-0A36-4DAC-8011-8A5C0A5994DFQ38562255-AF0BA156-236E-4E8C-A6FB-74E68E424F97Q38675216-8CCC8909-030A-4CBF-8E52-4FD0593097B3Q39186980-AABE9C94-C648-40C9-BF0D-AE1FC4AC81CAQ40410864-B8D2AB41-58DD-41D2-BFD4-249938FE6F17Q41893910-84758AF4-C262-4C30-BED0-D3C8E7967060Q42441161-18B53AE4-2A02-454B-A348-00FD2F7ED114Q47140929-1D084871-FA45-40D2-AC2C-D3168EAB1D53Q47373746-C8076550-316C-4E28-BA6C-EEAFA0FC2C12Q47553904-52DFF658-D78E-4AB0-87C2-EF894E6918CBQ47571147-B1C99A61-BB39-490B-AE36-C0D22A8D98F1Q47873490-FDE31CC3-1BAE-457D-9D8B-0769818449DEQ52315330-6B746DCD-4738-45A4-82FB-F9DAD0A1C385Q54222874-AC85E78C-223F-4F4B-BCA8-A1ADCCB0EAECQ54979695-0133A69B-7D00-450E-A560-8FC83F945E7BQ55380454-190CF88C-8E02-4A9F-85B7-F0AF2975AF6AQ57492342-A1141976-15B1-4E40-8B1E-114FBE0E94F6Q58794404-D12B0EBD-2525-4AA0-B70B-516223616CC1
P2860
CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@ast
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@en
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@nl
type
label
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@ast
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@en
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@nl
prefLabel
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@ast
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@en
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@nl
P2093
P2860
P1476
CCL2 affects β-amyloidosis and ...... model of Alzheimer's disease.
@en
P2093
E Elizabeth Higgins
Howard E Gendelman
Mohit Jain
Tomomi Kiyota
P2860
P304
P356
10.1016/J.NEUROBIOLAGING.2012.08.009
P577
2012-10-04T00:00:00Z